Thrombus News and Research

RSS

A blood clot or thrombus, is the final product of the blood coagulation step in hemostasis. It is achieved via the aggregation of platelets that form a platelet plug, and the activation of the humoral coagulation system (i.e. clotting factors).

Concentric Medical launches Trevo Pro 4 device for acute ischemic stroke

Concentric Medical, Inc. today announced the full European launch of Trevo Pro 4 System. This next standard in Stentriever technology has an enhanced design to further promote clot integration across clot types in patients suffering an acute ischemic stroke.

6 Sep 2011

Gore receives positive reports related to GORE HELEX Septal Occluder

W. L. Gore & Associates today reported that it has received zero accounts of erosion of the aortic root or the free wall of the atrium associated with the worldwide use of the GORE® HELEX® Septal Occluder.

23 Aug 2011

MindFrame receives CE mark approval for Capture LP and Flow LP devices

MindFrame Inc. today announces receiving CE mark approval for the MindFrame Capture LP™ and MindFrame Flow LP™ devices. Part of the comprehensive portfolio of MindFrame Therapy Solutions™, these low profile devices can be deployed through a smaller microcatheter to improve access through tortuous vessel anatomies.

2 Aug 2011

ThromboView gets positive results in study evaluating accuracy and safety

Drug and diagnostic company Agenix Limited (ASX: AGX), today announced the positive results of a study to evaluate the efficacy and accuracy

7 Jul 2011

Spectranetics initiates enrollment in EXCITE clinical trial against femoropopliteal IRS

Spectranetics Corporation today announces the first patient enrollment in the EXCITE ISR (EXCImer Laser Randomized Controlled Study for Treatment of FemoropopliTEal In-Stent Restenosis) clinical trial.

27 Jun 2011

FDA grants Pathway marketing clearance for JETSTREAM Navitus revascularization catheter for PVD

Pathway Medical Technologies, Inc, an innovator of endovascular treatments for peripheral vascular disease (PVD), announced today that the U.S. Food and Drug Administration (FDA) has granted the company 510(k) clearance to market JETSTREAM Navitus, an enhanced revascularization catheter for the treatment of PVD.

6 Jun 2011

Spectranetics to showcase new advanced peripheral atherectomy simulation system at New Cardiovascular Horizons

Spectranetics Corporation today announced it will showcase a new advanced peripheral atherectomy simulation system at the New Cardiovascular Horizons meeting in New Orleans.

31 May 2011

FDA grants approval for CSI to complete enrollment in ORBIT II IDE coronary clinical trial

Cardiovascular Systems, Inc. has received FDA approval to complete enrollment of 429 patients in its ORBIT II Investigational Device Exemption clinical trial for a coronary application for its Diamondback 360 System.

25 May 2011

Clinical data of Medtronic's Resolute drug-eluting stent in diabetes presented at EuroPCR meeting

For patients with both heart disease and diabetes who took part in a pooled series of rigorous clinical trials, the Resolute drug-eluting stent from Medtronic, Inc., provided remarkably safe and effective outcomes, according to the results of several studies presented today at EuroPCR, a major international meeting for cardiac and vascular specialists.

From Medtronic 18 May 2011

Spectranetics revenue increases 5% to $30.4 million for first quarter 2011

Spectranetics Corporation today reported financial results for the quarter ended March 31, 2011.

27 Apr 2011

VDF seeks nominations for PAD and venous disease research awards

The Vascular Disease Foundation is seeking nominations for research awards through its Peripheral Arterial Disease and Venous Disease Coalitions. Research awards recognize the important research relevant to the understanding and/or treatment of arterial and venous diseases.

25 Apr 2011

Boehringer Ingelheim's dabigatran etexilate receives positive opinion from EMA committee

Boehringer Ingelheim's novel oral anticoagulant dabigatran etexilate, received a positive opinion from the European Medicines Agency's medicinal committee today.

16 Apr 2011

Japanese MHLW approves Spectranetics LLD lead locking device

Spectranetics Corporation today announced that the Japanese Ministry of Health, Labor and Welfare granted approval for the LLD lead locking device, which is used for the removal of pacemaker and defibrillator cardiac leads.

6 Apr 2011

Pathway Medical initiates enrollment in JETSTREAM G3 Calcium Study in peripheral artery disease

Pathway Medical Technologies, Inc., an innovator of endovascular treatments for peripheral vascular disease (PVD), today announced enrollment of the first patient in the company's JETSTREAM G3 Calcium Study, a prospective, single-arm, multi-center registry to evaluate the treatment effects of the JETSTREAM G3 System in patients with moderate to severely calcified peripheral artery disease.

28 Mar 2011

FDA grants CSI marketing clearance for Stealth 360° Orbital PAD System

Cardiovascular Systems, Inc. has received 510(k) marketing clearance from the U.S. Food and Drug Administration (FDA), and has begun a limited market release for the Stealth 360°™ Orbital PAD System. The Stealth 360° propels CSI into the forefront of treating peripheral arterial disease (PAD) with a simpler design that gives physicians complete control of device operation.

17 Mar 2011

Argon acquires global rights to market, distribute Rex Medical's Option Retrievable Inferior Vena Cava Filter

Argon Medical Devices, Inc. announced today that it has entered into a definitive license agreement with Rex Medical, LP ("Rex Medical") for exclusive global rights to market and distribute the Option™ Retrievable Inferior Vena Cava Filter, an implantable device used in the prevention of Pulmonary Embolism (PE).

15 Mar 2011

BIOTRONIK's new ablation catheter is now available in Europe

BIOTRONIK SE Co. & KG, a leading manufacturer of cardiac devices, has announced that its innovative new ablation catheter, AlCath Flux eXtra Gold, is now available throughout Europe after receiving CE mark and successfully completing the premarket evaluation in Germany, Italy, Switzerland and several other European countries.

9 Mar 2011

New cell therapy can reverse effect of 'bad' LDL cholesterol and reduce atherosclerosis

Researchers at the Swedish medical university Karolinska Institutet have shown in a new study on mice, that cell therapy can be used to reverse the effect of 'bad' LDL cholesterol and reduce the inflammation that leads to atherosclerosis.

1 Mar 2011

Hotspur Technologies announces first clinical use of its Keeper Embolectomy Catheter

Hotspur Technologies announced today that Dr. Thomas DiBartholomeo of Fairfield, CT, performed the first clinical use of its Keeper Embolectomy Catheter. The Keeper Catheter enables physicians to clear clot formation within arteries, while also incorporating the capability of injecting physician-specified fluids directly through the balloon catheter.

28 Feb 2011

Spectranetics fourth quarter revenues decrease 1% to $29.3 million

Spectranetics Corporation today reported financial results for the quarter and full year ended December 31, 2010.

17 Feb 2011